What is Leerink Partnrs' Estimate for PTGX Q3 Earnings?

Key Points

• Leerink Partners estimates Protagonist Therapeutics will report Q3 2025 earnings per share of ($0.60), with a full-year expectation of ($1.95) EPS.
• The stock currently has a consensus "Buy" rating, with price targets ranging from $67.00 to $80.00 among various analysts.
• Insider transactions revealed significant stock sales, with CEO Dinesh V. Patel selling 10,415 shares and Director William D. Waddill selling 4,000 shares recently.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at Leerink Partnrs issued their Q3 2025 earnings estimates for shares of Protagonist Therapeutics in a research note issued to investors on Friday, September 12th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.60) for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.43 per share. Leerink Partnrs also issued estimates for Protagonist Therapeutics' Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS.

A number of other analysts have also recently weighed in on the stock. JMP Securities raised their price target on shares of Protagonist Therapeutics from $67.00 to $69.00 and gave the company a "market outperform" rating in a report on Thursday, August 7th. Barclays assumed coverage on shares of Protagonist Therapeutics in a research note on Wednesday. They issued an "overweight" rating and a $72.00 target price for the company. Wall Street Zen upgraded shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 8th. Leerink Partners assumed coverage on shares of Protagonist Therapeutics in a research note on Friday, September 12th. They issued an "outperform" rating and a $73.00 target price for the company. Finally, Citigroup reiterated an "outperform" rating on shares of Protagonist Therapeutics in a research note on Thursday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics has a consensus rating of "Buy" and an average target price of $68.08.

Protagonist Therapeutics Trading Up 0.1%

Shares of NASDAQ:PTGX traded up $0.06 during trading on Monday, reaching $62.20. The stock had a trading volume of 2,461,714 shares, compared to its average volume of 963,430. Protagonist Therapeutics has a one year low of $33.31 and a one year high of $63.30. The company has a market capitalization of $3.87 billion, a P/E ratio of 88.86 and a beta of 2.22. The firm's 50-day simple moving average is $56.56 and its 200 day simple moving average is $51.45.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.02). Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. The firm had revenue of $5.55 million during the quarter, compared to the consensus estimate of $8.32 million.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. raised its position in Protagonist Therapeutics by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company's stock worth $74,000 after acquiring an additional 275 shares during the period. Guggenheim Capital LLC grew its holdings in shares of Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company's stock worth $1,062,000 after buying an additional 303 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company's stock worth $28,000 after buying an additional 318 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of Protagonist Therapeutics by 4.1% during the first quarter. Hsbc Holdings PLC now owns 8,458 shares of the company's stock worth $405,000 after buying an additional 330 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Protagonist Therapeutics by 16.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company's stock worth $132,000 after buying an additional 340 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 10,415 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $54.78, for a total transaction of $570,533.70. Following the completion of the sale, the chief executive officer directly owned 520,603 shares in the company, valued at approximately $28,518,632.34. The trade was a 1.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $59.25, for a total transaction of $237,000.00. Following the sale, the director owned 9,130 shares of the company's stock, valued at approximately $540,952.50. The trade was a 30.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,859 shares of company stock valued at $3,687,577. Company insiders own 4.90% of the company's stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.